Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Core Insights - Nurix Therapeutics presented new clinical data for bexobrutideg, a BTK degrader, showing an objective response rate (ORR) of 75.0% in heavily pre-treated Waldenström macroglobulinemia patients [1][4] - The drug demonstrated durable responses and was well tolerated, with no dose-limiting toxicities reported [2][3] - The company aims to position bexobrutideg as a best-in-class therapeutic option for various hematological malignancies [2] Clinical Data Summary - The Phase 1 trial included 31 patients with a median age of 71 years and a median of 3 prior lines of therapy [2][4] - Among the patients, 77.4% had MYD88 mutations and 19.4% had CXCR4 mutations, with 100% having prior BTK inhibitor treatment [2] - The ORR included very good partial responses (VGPR) in 10.7% of patients, partial responses (PR) in 50.0%, and minor responses (MR) in 14.3% [4] Safety and Tolerability - Bexobrutideg was well tolerated, with common adverse events being low grade, including neutropenia (29.0%) and diarrhea (25.8%) [3] - No new onset atrial fibrillation was observed, and only two treatment-emergent adverse events led to drug discontinuation [3] Future Development - The company plans to expand the development of bexobrutideg into chronic lymphocytic leukemia (CLL) and other non-Hodgkin lymphoma (NHL) indications [2][8] - Nurix is also advancing multiple other drug candidates in its pipeline, focusing on targeted protein degradation [9]